Author: Neel Achary

Bombay Dyeing Marks World Sleep Day 2026 with ComfortThatCares

Mumbai, Mar 12: As India navigates rising stress, digital fatigue, and increasingly disrupted routines, Bombay Dyeing & Manufacturing Company Ltd. is using World Sleep Day 2026 to spotlight a simple but important idea: better sleep begins with a better sleep environment. This year’s theme, “Sleep Well, Live Better,” is a timely reminder that sleep is not something to be earned at the end of a productive day; it is what makes that productivity possible in the first place.

 That is the belief at the heart of ComfortThatCares, Bombay Dyeing’s World Sleep Day initiative. Through this campaign, the brand is shifting the conversation from simply sleeping more to sleeping better, drawing attention to the role that thoughtful, quality home textiles play in creating a sleep environment that truly supports rest. Bombay Dyeing’s sleep portfolio is engineered specifically to address these environmental factors:

• Urban Living Luxury Bedsheets: 400-thread-count cotton blends that are highly breathable, helping regulate body temperature to prevent midnight waking.

• Celebrating India Collection: 100% pure cotton in a rich 300 thread count, offering soft, breathable comfort with heritage-inspired designs.

• Comforters: Lightweight, breathable filling designed to provide year-round comfort without overheating.

• Bonded Blankets: Thick, insulated layers with a soft-touch finish for consistent, comfortable warmth through the night.

• Pillow: Thoughtfully engineered for optimal support and breathable comfort, Bombay Dyeing pillows are designed to change how India sleeps. By balancing plush softness with ergonomic support, they ensure restorative rest night after night, making everyday luxury a part of your daily routine.

The Brand Marketing Team of Bombay Dyeing adds,

“Sleep is foundational to our physical and mental well-being. Through #ComfortThatCares, we want to encourage families across India to treat sleep as essential, not an afterthought. At Bombay Dyeing, we have spent 145 years crafting products that bring comfort into Indian homes – and there is no comfort more important than a good night’s rest.”

For millions of Indians, sleep is the first thing sacrificed to a long day. Late-night screens, irregular schedules, and mounting pressures have quietly eroded the quality of rest that most people get. And yet, sleep affects nearly every aspect of how we function: how clearly we think, how well we recover, and how we show up for the people around us. Most healthy adults need 7 to 9 hours of quality sleep, and research consistently shows that the environment in which we sleep plays a significant role in whether we actually get it.

Soft, 100% cotton bedsheets that keep you cool, dohars that are light but cosy, pillows that properly support your neck, and blankets that keep you warm through the night. Every product in Bombay Dyeing’s sleep range is built on a simple idea: what you sleep on matters just as much as how long you sleep.

CERo Therapeutics Provides Shareholder Update

SOUTH SAN FRANCISCO, Calif., March 11, 2026 — CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, provides an update through the letter to stockholders and stakeholders from CEO Chris Ehrlich:

To our stockholders and stakeholders:

Following our recent Form 8-K filing confirming receipt of convertible debt funding to support current operations, we believe it is an appropriate time to provide an update on CERo Therapeutics’ operational and scientific progress. Over the past six months, the Company has advanced its clinical development activities, engaged in strategic discussions, and continued to manage resources with fiscal discipline.

During this period, we have progressed the development of our lead candidate, CER-1236, including observations consistent with an acceptable safety and tolerability profile to date, across multiple treated patients. We have also observed biologic activity consistent with the mechanism of the therapy, including approximately 20–70-fold cell expansion, peaking between days 7–14 and followed by continued persistence as measured in peripheral blood. These early observations contribute to our understanding of CER-1236 and support continued clinical evaluation of the program.

Notably, in the second patient treated in our ongoing Phase I study, we observed an interval of apparent disease stability during which the patient’s disease progression and requirement for platelet transfusion support did not increase following multiple infusions of CER-1236. While this is an early observation from a single patient and Phase I studies are primarily designed to evaluate safety, we believe the clinical course of this patient is noteworthy.  This patient had previously been diagnosed with myelodysplastic syndrome (MDS), a disorder of the bone marrow that can progress to acute myeloid leukemia (AML).

The emerging clinical observations provide an early signal that supports continued investigation of CER-1236. These data are helping guide the Company’s ongoing development strategy, including exploration of dosing approaches and patient selection in future cohorts.

While CER-1236 demonstrated activity across multiple tumor models during preclinical development, the observations to date in the MDS setting highlight a potentially important area for further study. We believe these early findings may also support future discussions with potential strategic partners regarding the continued development of the program.

Progress in Phase 1 Clinical Trial and Strategic Focus on MDS
We recently announced data from our ongoing CERTAIN-T Phase 1 clinical trial that reflects the Company’s current development approach for our lead compound, CER-1236. Based in part on early clinical observations in a patient with MDS, a disorder of the bone marrow that can precede AML, the Company has refined its development strategy to increase focus on enrolling patients with MDS while maintaining optionality in AML.

This strategic refinement was informed in part by observations from a patient who received four infusions of CER-1236 over approximately five months at the lowest dose level in the study.

As previously announced, prior to receiving CER-1236 the patient required frequent platelet transfusions. During the period following treatment in the study, the patient experienced an interval of platelet transfusion independence lasting more than two months, exceeding the commonly referenced ≥56-day durability benchmark used in MDS studies.

The Company is actively seeking to enroll additional patients with similar clinical characteristics to further evaluate this observation. If similar findings are observed in additional patients, these data may help inform future discussions with regulatory authorities and potential strategic partners regarding the continued development of CER-1236.

To date, the Company has initiated the second cohort of the trial, and two additional patients have recently undergone apheresis, a procedure in which blood cells are collected to manufacture CER-1236 for each individual patient. The Company plans to initiate dosing for these patients during March and April.

Pursuing a Strategy to List on a Major Exchange
Re-establishing our listing on a major exchange remains one of our key priorities.  To that end, we have engaged with an investment bank to raise capital and pursue a strategy intended to support a potential relisting on the Nasdaq Capital Market.  We believe that our new partner’s institutional relationships and sector expertise align well with our goal of raising sufficient capital in a disciplined manner while attracting longer-term, knowledgeable investors who are familiar with the clinical development landscape and strategic direction. In addition, we are considering other potential paths for relisting on a national securities exchange, including potential business combinations with listed companies, which may include a reverse merger or a business combination with a special purpose acquisition company.

Continued Funding Support
As recently disclosed, as we pursue new financing opportunities and seek to relist on Nasdaq, our lead investor continues to support CERo’s operations through investments in convertible debt. Their commitment to CERo has enabled us  to sustain operations and advance our clinical programs. We believe our clinical development and focus on our financing efforts and strategy for relisting on Nasdaq will be beneficial to all CERo stockholders and are grateful for the continued confidence our loyal stockholder base.

Strategic Discussions Regarding Early Data Readouts
We continue to engage in ongoing discussions with potential strategic partners following the most recent data readouts, as is regularly seen in the biotech industry. While these  conversations are encouraging, they remain at an early stage and have not resulted in formal agreements. We believe the evolution of our strategy and growing dataset may catalyze future conversations. To the extent permitted under applicable law and contractual obligations, we expect to provide further updates to stockholders should any of these discussions advance in a manner that materially impacts the Company.

Board Expansion – Appointment of Eric Francois
Finally, we recently announced that Eric Francois joined our board of directors.  Eric brings decades of experience in life sciences finance, capital markets, and corporate development, including deep expertise in capital raising, M&A, and strategic partnerships.  His involvement with the Company is among multiple catalysts that, we believe, will positively impact CERo in the months to come.  Eric was instrumental in our discussions with our new investment bank and is already assisting with other potential funding opportunities, operational improvements, and external viewpoints on the Company’s next phase of growth.

Dedicated, Engaged Professionals Working Together to Achieve Success
It should never go without saying that CERo’s world class team – employees, partners, consultants, and advisors – all remain focused and excited about achieving the common goal of improved patient care and improving patients’ lives through innovative clinical development.  Despite challenges that might have derailed other companies several times over, the CERo team has continued to perform with enthusiasm toward the achievement of bringing CER-1236 to the next inflection point and beyond.

Our take-home message is clear:  CERo is operational, continuing to advance our clinical programs, and generally building momentum. We are committed to transparent communication, and we look forward to sharing the outcomes of each of our ongoing activities in the future. We thank you for your continued support and confidence in our novel approach to treatment and our leadership.

Sincerely,
Chris Ehrlich
CEO
CERo Therapeutics

Fitell Announces Corporate Name and Ticker Changes and Rebranding to GMEX Robotics

Company extends its consumer-first foundation beyond fitness equipment e-commerce into the design and deployment of AI-powered robotics and intelligent consumer technologies

Sydney, Australia, March 11, 2026 — In a move that redefines its corporate identity and market trajectory, Fitell Corporation (NASDAQ: FTEL) (“Fitell”, “GMEX Robotics” or the “Company”) today announces its rebranding to GMEX Robotics. The rebrand reflects a deliberate strategic evolution of the Company’s mission, extending its consumer-first foundation beyond fitness equipment e-commerce into the design and deployment of AI-powered robotics and intelligent consumer technologies.

“This rebrand is a revolution in our ambition, but an evolution of our expertise,” said Sam Lu, GMEX Robotics CEO. “As Fitell, we built a robust operation centered on consumer needs. As GMEX Robotics, we amplify that focus by applying advanced artificial intelligence and robotics to solve real human problems. Our fitness and health division remains a vital part of our operations; it is our testing ground and our inspiration. It ensures that as we build sophisticated robots, we never lose sight of the human they are designed to serve.”

The Company filed its amended and restated memorandum and articles of association in accordance with the BVI Business Companies Act (as amended) and, effective March 2, 2026, completed its legal name change to “GMEX ROBOTICS CORPORATION ” pursuant to such filing (the “Name Change“). In connection with the Name Change, the Company will also change its ticker symbol on the Nasdaq Capital Market (the “Nasdaq”) from “FTEL” to “GMEX” (the “Ticker Change“).

The Company’s Class A ordinary shares (“Ordinary Shares“) are expected to commence trading on the Nasdaq under the new corporate name and new ticker symbol as early as market open on March 12th, 2026. In connection with the name and ticker changes, the Company’s CUSIP number will remain unchanged. No action is required by existing shareholders, nor will any certificates representing Ordinary Shares need to be exchanged.

The rebrand reflects the next phase of the company’s long-term vision. Effective immediately, GMEX Robotics will focus on designing, manufacturing, and commercializing AI-driven robotic solutions for the consumer market, building on its foundation of expertise in fitness and health products. This shift represents the Company’s commitment to leading the next technological wave, where intelligent machines become an integral part of daily life. Rather than a wholesale departure from its roots, GMEX Robotics will continue to operate its existing fitness and health-related product business, which remains the crucial operational foundation for future growth. This legacy vertical functions as a hands-on laboratory for understanding human movement, ergonomics, and daily routines. The deep understanding of consumer wellness garnered through years of serving the fitness market will directly inform the design and development of the Company’s next generation robotic products.

GMEX Robotics will focus its efforts on three primary pillars:

1. Consumer and Commercial Robotics: Developing intuitive and interactive robots designed to assist with daily tasks, provide smart home integration, and offer new levels of convenience and connectivity to boost productivity.
2. AI-Driven Hardware: Embedding advanced artificial intelligence into physical products to create self-learning and adaptive user experiences.
3. Innovation & Ecosystem: Building a robust ecosystem of robotic products that communicate and evolve, powered by proprietary AI algorithms.

While the Company’s history in the fitness sector provides a strong foundation in logistics, supply chain management, and consumer engagement, GMEX Robotics is now engineered for a different market. The Company is actively assembling a new leadership team and technical workforce specializing in mechatronics, computer vision, and machine learning to drive this ambitious agenda.

The transition from Fitell to GMEX Robotics signifies the close of one chapter and the exciting, bold beginning of another. The Company invites investors, innovators, and consumers to join them as they build the intelligent future.

M. P. Ahammad, Chairman of Malabar Group, Conferred Maharashtrian of the Year Award 2026 by Maharashtra CM Devendra Fadnavis

Chennai, Mar 11th: Mr. M.P. Ahammad, Chairman, Malabar Group, has been honoured with the prestigious Business Bhushan Award at the Lokmat Maharashtrian of the Year Awards 2026, in recognition of his visionary leadership and pivotal role in transforming the global jewelleryretail landscape and society at large.

Held at the iconic Gateway of India, the awards ceremony brought together leading policymakers, industry leaders, and prominent personalities from business and entertainment. The event was attended by the Chief Minister, Sri. Devendra Fadvanis, and Deputy Chief Minister, Sri. Eknath Shinde of Maharashtra, Sri. Vijay Darda, Chairman of Lokmat alongside ministers, bureaucrats, and distinguished figures from across sectors.

Presented by Lokmat Media Group, the awards celebrate individuals whose vision, leadership, and achievements have significantly shaped industries while contributing meaningfully to society. Mr. Ahammad’s recognition highlights his remarkable entrepreneurial journey and the role he has played in building Malabar Gold & to become the 5th largest global jewellery retailer and the largest jewellery retailer of Indian origin.

Expressing his gratitude on receiving the honour, Mr. M.P. Ahammad, Chairman, Malabar Group, said, “I am deeply honoured to receive the Business Bhushan award at the LokmatMaharashtrian of the Year Awards. This recognition reflects the collective dedication of the entire Malabar family and the trust our customers have placed in us over the years. Our journey is founded on the principle of collective growth of all our stakeholders guided by responsibility, integrity, and a commitment to creating lasting value for society while continuing to pursue excellence in everything we do.” 

Founded in 1993, Malabar Gold & Diamonds has been a pioneer in fostering responsible and transparent jewellery retail, contributing significantly to employment generation, strengthening the organised retail ecosystem, and enhancing customer experience through access to world‑class designs and services.

Today, the brand stands as a true flag bearer of India, showcasing the nation’s craft and soul to the world through its 425 showrooms across 14 countries. The brand has reimagined the jewellery industry by integrating the entire value chain, from design and manufacturing to retail and beyond.

Maharashtra remains a key market for Malabar Gold & Diamonds, now with 34 showrooms across major cities. This growth has boosted employment, strengthened the organised jewellery ecosystem, and improved access to quality designs. His substantial contribution to the state earned him this honour, and the Group is committed to further expansion, targeting 64 stores in Maharashtra by 2029.

Beyond business growth, Mr. Ahammad advanced a purpose‑driven model by embedding CSR/ESG commitments into the company since inception, consistently contributing 5% of profits to education, healthcare, housing support and women’s empowerment programmes, benefiting the society across regions of operations.

His recognition with the Business Bhushan Award further reinforces his stature as one of India’s most respected business leaders whose entrepreneurial vision and values-driven leadership serve as an inspiration and a blueprint for collective progress for future global enterprises.

Urban Square Mall Celebrates Women’s Day with Beauty, Wellness and Shopping Delights

Celebrating the spirit, strength and grace of women, Urban Square Mall hosted a vibrant Women’s Day celebration on 7th and 8th March, bringing together beauty, wellness and shopping experiences for visitors. The two-day event created a lively and engaging atmosphere, encouraging women to celebrate themselves and the many roles they play in everyday life.

As part of the celebration, visitors enjoyed complimentary makeovers by leading beauty brands including Swiss Beauty, Forever 52 and Mars Cosmetics, along with free nail art sessions, giving women an opportunity to pamper themselves and embrace their personal style. The initiative witnessed enthusiastic participation from shoppers who enjoyed the special services and festive ambience at the mall.

Adding a meaningful dimension to the event, Dr. Nitisha Sharma conducted an insightful session on Women’s Health and Nutrition in collaboration with Mamaearth, where attendees gained valuable tips on maintaining a healthy lifestyle and prioritising self-care. The interactive session was well received, highlighting the importance of wellness alongside celebration. Visitors also received exclusive shopping vouchers, adding excitement to the festive shopping experience.

On the occasion, women customers, retail staff, and mall operations and service staff were also welcomed with roses and chocolates as a token of appreciation and gratitude for their contribution in making the mall ecosystem vibrant and successful.

Speaking on the occasion, Nandini Taneja, Chief Executive Officer, Bhumika Enterprises, said, “Women’s Day is a wonderful opportunity to celebrate the strength, confidence and individuality of women. Through this initiative, we wanted to create a space where women could relax, engage, learn and feel appreciated. At Urban Square Mall, we are committed to hosting experiences that bring the community together and celebrate moments that truly matter.”

Toing, the Affordable Food App, Launched in Mumbai

Mumbai, Mar 11th: Toing, the affordable food delivery app, today announced its launch in Mumbai. Over the last 7 months, Toing has expanded to 18 cities across India and is also live in Pune, Agra, Vadodara, Guwahati, Nashik, Nagpur, Patna, Aurangabad, Bhopal, Delhi, Gurugram, Noida, Faridabad, Ghaziabad, Chandigarh and Ahmedabad. Toing promises the lowest item prices across food/ beverages on its app, guaranteeing to match or beat restaurant table menu prices. In addition to this, there are no packaging charges or platform fees on any order. This will make Toing the most affordable food delivery app available in the market. Users can order a range of dishes including biryanis. 

Toing, which was launched in the second half of 2025 with Pune as the first city, has now gone live in Mumbai with some of the famous restaurants from the city already listed on the platform. Toing‘s affordable and accessible pricing model has strongly resonated with first-time jobbers and college students, accelerating its expansion to newer cities. By focusing on everyday affordability, Toing ensures unmatched value and reliability for its users. The app features some of Mumbai’s most popular restaurants such as Meraki, Punjab Depot, Sweet Country Cake Shop, Borivali Biryani Centre, Sandwizza, Thepla House, Theobroma, Burger King, Faaso’s, Tacobell, Wendy’s, Dabba Garam, Charcoal Eats – Biryani & Beyond, Tibb’s Frankie, YBFC, Cheelizza – India Ka Pizza, Ghost Kitchens, Sadak Chaap, Peetuk, House of Biryan- Biryani, Kepsa and More, Tea Post, Marrakesh, Rolls Mania – Rolls, Wraps & More, Mad Momos, offering a wide range of food options across cuisines including North Indian food like Chole Bhature, Biryani, North Indian dishes, Chinese, Desserts and fast-food options like Pizzas, Burgers, and Momos. 

Speaking on the expansion, Mr. Sidharth Bhakoo, Chief Business Officer, Toing said, “Toing is creating a new category of food customers targeting the Gen Z, college goers and the value conscious customers and it guarantees lowest prices to its customers. Recently, we launched Toing in key educational hubs- like Guwahati, Nashik, Nagpur and in Delhi NCR. This expansion reflects both the strength of the value proposition and our commitment to serve the evolving needs of young consumers. Mumbai has a large base of Gen Z and college goers and hence, offers the perfect landscape for Toing.” 

With more than 2 million downloads across India and a remarkable rating of 4.5, Toing appears to be emerging as a strong alternative in the value-driven food delivery space.